Ann: Quarterly Activity Report & Appendix 4C, page-9

“It is a critical validation step for Cynata’s ongoing commercial partnering activities.

CASH still $23.8m”

Not enough to afford the paper clips for a FDA trial.


Oh, it’s critical. No argument there!

Ongoing commercial partnering activities. Right-o!

Does anyones else think that they have no leverage to negotiate?

They are totally reliant on Ross’ negotiation skills. And any potential partner knows they haven’t got the financial resources to do the trial alone.

Let’s see how Ross does. By the end of the year.

Together we are all going to watch this unfold. I can’t wait!

Go, Ross!!